Atlanta Catheter Therapies Selected for Investor Conferences

Innovative Intravascular Catheterization Integrated With Drug Delivery Draws Interest


ATLANTA, GA and BOSTON, MA--(Marketwire - April 19, 2010) -  Atlanta Catheter Therapies, Inc. (ACT) has been selected to present at the Biotech & Healthcare Venture Summit 2010, presented by youngStartup Ventures, in Boston on April 20, 2010. ACT is focused on developing innovative catheter technologies for the treatment of vascular disease and restenosis.

The Summit is the premier bioscience industry gathering, connecting senior executives of early stage biotech, pharmaceutical, healthcare, medical device and diagnostic companies with venture capitalists (VC), angel investors, corporate VCs and professional service firms.

ACT was also one of 12 companies selected to present at the annual medical device conference of the Southeastern Medical Device Association (SEMDA) on March 25, 2010. The company generated strong interest from the attending VCs and angel investors, who represented a total of $3 billion in funds.

ACT recently announced that its lead product, an innovative catheter that integrates drug delivery with vascular catheterization, has completed the prototyping phase. The Occlusion Perfusion Catheter™ (OPC) allows endovascular specialists who have already cleared blocked blood vessels to then immediately circumferentially infuse the media with an agent or live cell to reduce or eliminate restenosis (re-blockage). The OPC follows the same guide wire used by the debulking catheter to deliver anti-restenosis agents or drugs and other therapies directly and precisely to the treatment site.

In addition to the OPC, the company is attacking the problem of vascular disease by developing leading edge technology for atherectomy, thrombectomy and other catheter-based devices. ACT currently has seven devices in its product development pipeline, including the OPC.

"Each device is being designed and developed with targeted improvements over any existing device already on the market," said ACT CEO Paul Fitzpatrick. "These design improvements will vastly advance the efficacy of the treatment of vascular disease and restenosis and address the enormous problem associated with these conditions worldwide."

About Atlanta Catheter Therapies
Atlanta Catheter Therapies is an early stage research and development medical device company with an innovative and targeted portfolio of catheter technologies for the treatment of vascular disease and restenosis. Learn more at www.atlcath.com.

Contact Information:

Media Contact: Lynn Hood, , 770-321-8439